<unk>  is the most frequent cause of death following<unk><unk> . According to the timing,<unk>  can be divided into three sections; First month after<unk> , 1 to 6 months after<unk> , and more than 6 to 12 months after<unk> . Prevention of<unk>  includes Screening potential<unk>  donors and recipients for<unk> , certain vaccines such as pneumococcal and influenza vaccines should be repeated after<unk>  in an attempt to lower the risk for these diseases. Empiric broad-spectrum antibiotics should be initiated if a bacterial<unk>  is suspected in a<unk>  transplant recipient until the specific bacterium and its sensitivities can be identified. Antibiotic regimens should include coverage for gram-positive cocci, gram-negative bacilli and anaerobes. In patients without sulfonamide allergy, trimethoprim-sulfamethoxazole is generally administered for 6 to 12 months after<unk><unk>  to reduce the risk of pneumocystis jirovecii pneumonia, listeria monocytogenes, nocardia, and toxoplasma gondii. Prophylaxis of CMV includes Ganciclovir and valganciclovir are used to prevent CMV<unk>  in patients at risk of CMV reactivation for three to six months. Prophylaxis of candida includes Fluconazole 400 mg orally daily is the drug of choice for one to four weeks or for as long as risk factors persist. Prophylaxis of aspergillosis includes Fluconazole prophylaxis decreased invasive fungal<unk> s by 75 percent.
Liver transplantation infection
Drug induced liver injury medical therapy
Acute liver failure surgery
Hepatorenal syndrome surgery
Alcoholic liver disease surgery
Chronic liver disease medical therapy
Autoimmune hepatitis surgery
Cirrhosis surgery